The exosomal PD-L1 can inhibit antitumor immunity and may be resistant to anti-PD-L1 antibody blocking, so it can be used as a potential biomarker for evaluating drug efficacy and early prediction of malignant tumors (42). The gene discussed is CD274; the disease is cancer.